Thu, Apr 24, 2014, 4:33 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • metsny97 metsny97 Sep 16, 2010 3:39 AM Flag

    Blockbuster Phase3 results this MONTH=$$$$$$$$$$$$$

    BNC is the next DENDREON .Please do your own DUE DILIGENCE !

    POSITIVE PHASE 3 RESULTS WILL PUSH THIS STOCK TO $4-6 EASILY .PHASE 3 SUCCESS WILL TRIGGER A 50 MIL$+ MILESTONE PAYMENT TO BNC


    Urocidin (Bladder Cancer) Phase3 results in September .Phase 3 results will be positive (VERY VERY LOW RISK )..


    Bioniche Life Sciences (TSX: BNC)

    Market Cap: 72 Mil$
    Cash: 22 Mil $
    Price: 0,99 $


    * BUY RATING BY DUNDEE SEC *

    Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.

    Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.

    Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.

    A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.

    In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.

    “Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .

















    GOOD LUCK TO ALL !!!!!!!!!

 
OGXI
10.52+0.09(+0.86%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.